GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Exagen Inc.
Exagen specializes in diagnostic tests for autoimmune diseases. Its stock price reflects its efforts to increase market penetration of its flagship AVISE CTD test. The chart tells the story of its struggle for acceptance by doctors and insurance companies.
Share prices of companies in the market segment - Medanalysis
Exagen Inc. is a life sciences company that develops and markets diagnostic tests for autoimmune diseases. We've categorized it as a "Medical Analysis" company. The chart below shows how investors view the diagnostics sector for complex and difficult-to-detect diseases.
Broad Market Index - GURU.Markets
Exagen is a life sciences company that develops and markets diagnostic tests for autoimmune diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how its stock compares to the diagnostics sector.
Change in the price of a company, segment, and market as a whole per day
XGN - Daily change in the company's share price Exagen Inc.
For Exagen, a diagnostics company, change_co is a measure of volatility in the medical technology sector. Daily fluctuations reflect the reaction to the adoption of its autoimmune disease tests. This metric is important for analyzing innovative diagnostics companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Medanalysis
Exagen Inc. is a diagnostics company. This chart highlights the high volatility of the healthcare sector. Comparing it to XGN, which focuses on autoimmune disease testing, helps us understand its innovative nature.
Daily change in the price of a broad market stock, index - GURU.Markets
Exagen specializes in autoimmune disease diagnostics. The company's shares react to news of its tests' acceptance by the medical community and to research data. This specific volatility, driven by medical innovation, feeds into the overall market flow, shaping its daily pattern.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Exagen Inc.
Exagen Inc.'s year-over-year performance is a story of the rollout of its diagnostic tests for autoimmune diseases. Its 12-month market cap reflects its success in convincing doctors and insurance companies of the value of its AVISE tests, which aid in the early diagnosis of complex conditions like systemic lupus erythematosus.
Annual dynamics of market capitalization of the market segment - Medanalysis
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. Its innovative products help doctors make diagnoses. The chart shows how its scientific advancements, test commercialization efforts, and competition in the diagnostics sector influence its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Exagen, which specializes in autoimmune disease diagnostics, operates in the defensive healthcare sector. Demand for its tests is unaffected by economic cycles. The company's stock performance reflects its success in commercialization and innovation, making it a growth story isolated from general market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Exagen Inc.
Exagen, a diagnostics company, depends on the adoption of its tests for its products. The monthly fluctuations on the chart reflect the volume of its autoimmune disease tests and, more importantly, the reimbursement rates from insurance companies, which determine its profitability.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. This medical diagnostics sector is at the forefront of personalized medicine. The chart below reflects investors' belief in the potential of innovative tests for the early and accurate diagnosis of complex diseases, which could radically change treatment approaches.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Exagen is a diagnostic company specializing in tests for autoimmune diseases. Its stock price depends on the acceptance of its tests by doctors and insurance companies. It's a story about the commercialization of medical innovation, where every quarterly sales report is crucial.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Exagen Inc.
Exagen Inc. is a company specializing in diagnostic tests for autoimmune diseases. Its weekly stock price is driven by the pace of physician adoption of its tests, insurance coverage news, and progress in developing new diagnostic products.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Exagen specializes in diagnostic tests for autoimmune diseases. Its success depends on the adoption of these tests in clinical practice and the decisions of insurance companies. The chart below shows how Exagen shares react to internal news compared to the overall sentiment in the medical diagnostics sector. Is this a growth story or an industry trend?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Exagen operates in the medical diagnostics industry. The company's success depends on the clinical adoption of its tests, not the state of the economy. This chart shows how the company's shares have a life of their own, often ignoring general market fluctuations and moving based on internal news and data.
Market capitalization of the company, segment and market as a whole
XGN - Market capitalization of the company Exagen Inc.
Exagen's market capitalization reflects its focus on autoimmune disease diagnostics. The volatility on its chart reflects how investors assess the commercial potential of its AVISE® tests. The company's valuation depends on its ability to convince physicians and insurance companies of the clinical value and cost-effectiveness of its diagnostic solutions.
XGN - Share of the company's market capitalization Exagen Inc. within the market segment - Medanalysis
Exagen specializes in developing and selling diagnostic tests for autoimmune diseases. Its market share is small, but it occupies an important niche in rheumatology. Its performance chart reflects the potential of its unique tests to help doctors make complex diagnoses.
Market capitalization of the market segment - Medanalysis
Here's a chart showing the market capitalization of the medical diagnostics sector. Exagen specializes in tests for diagnosing autoimmune diseases such as lupus. The size of this market reflects the complexity and prevalence of these diseases. Exagen aims to fill this niche by offering doctors more accurate diagnostic tools.
Market capitalization of all companies included in a broad market index - GURU.Markets
Exagen is a company that diagnoses autoimmune diseases. Its tests help doctors make accurate diagnoses. The company's market capitalization reflects the importance of accurate and timely diagnostics. The chart below shows the economic weight of the specialized medical testing sector.
Book value capitalization of the company, segment and market as a whole
XGN - Book value capitalization of the company Exagen Inc.
Exagen's book value is derived from its laboratories and intellectual property for diagnostic tests for autoimmune diseases. The company's foundation is its scientific and technological base. The chart tells the story of how the company invests in the development and commercialization of unique diagnostic tools, building its assets.
XGN - Share of the company's book capitalization Exagen Inc. within the market segment - Medanalysis
Exagen develops diagnostic tests for autoimmune diseases. The chart shows its share of real assets. These are its certified laboratories, equipped with sophisticated equipment, which provide the necessary resources for conducting unique analyses.
Market segment balance sheet capitalization - Medanalysis
Exagen, a diagnostics company, is a capital-intensive business due to its need to own advanced and expensive laboratories. The graph below illustrates the scale of the entire medical services sector, highlighting the uniqueness of its infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Exagen specializes in diagnosing autoimmune diseases. The company's assets include its laboratories and diagnostic equipment. Its stake in BCap_All provides the necessary resources to conduct complex analyses, providing doctors and patients with clarity in the fight against difficult-to-diagnose diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Exagen Inc.
Exagen is a diagnostics company. The market premium to its laboratory assets reflects the valuation of its unique tests for diagnosing autoimmune diseases. The chart shows how the market perceives its ability to expand the use of these tests and achieve reimbursement from insurers.
Market to book capitalization ratio in a market segment - Medanalysis
Exagen specializes in diagnostic tests for autoimmune diseases. Its value lies in its unique methodologies and data. This chart shows how the market values its intellectual property and the commercial potential of its tests, offering a premium to the modest value of its laboratory assets.
Market to book capitalization ratio for the market as a whole
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. The company's value lies in its unique technologies and data, not in its physical laboratories. This chart illustrates how market valuation in the advanced diagnostics space can exceed book value due to its potential to transform treatment approaches.
Debts of the company, segment and market as a whole
XGN - Company debts Exagen Inc.
Exagen Inc., a company specializing in diagnostic tests for autoimmune diseases, is using capital to commercialize its products. Its debt strategy is aimed at funding work with physicians and insurance companies to expand the adoption of its tests. This chart reflects the investments needed to advance innovative diagnostics.
Market segment debts - Medanalysis
Exagen specializes in diagnostic tests for autoimmune diseases. In the medical diagnostics industry, investing in research and obtaining regulatory approvals is key. This chart shows the company's financial approach to funding its development, which may indicate its confidence in future products and their commercial potential.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Exagen Inc.
Exagen specializes in diagnostic tests for autoimmune diseases. Developing and commercializing such tests is a capital-intensive process. This chart shows the company's debt-to-asset ratio. This is a key indicator for assessing the company's funding status and its reliance on external lenders for R&D.
Market segment debt to market segment book capitalization - Medanalysis
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. The chart shows debt trends in the medical analytics sector. For a company dependent on physician adoption of its tests, this allows it to assess how it finances commercialization and research, and how its financial policies compare to other players in the diagnostics field.
Debt to book value of all companies in the market
Exagen specializes in autoimmune disease diagnostics. For companies in the medical diagnostics sector, investments in research and laboratory equipment are key. This chart shows the overall level of debt in the market. It helps us understand whether Exagen prefers to finance its innovations with shareholders or whether it resorts to debt in line with overall market trends.
P/E of the company, segment and market as a whole
P/E - Exagen Inc.
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. This chart reflects how the market perceives the commercial potential of its unique products. The company's valuation is based on expectations of widespread adoption of its tests by physicians, which should lead to revenue growth and future profitability.
P/E of the market segment - Medanalysis
This chart for the medical diagnostics sector is a benchmark for Exagen. It reflects investors' general expectations for the growth of personalized medicine. Comparison with it helps understand whether Exagen's focus on autoimmune disease diagnostics, particularly lupus, is seen as more or less promising than companies operating in other diagnostics areas.
P/E of the market as a whole
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. The company's success depends on the acceptance of its tests by the medical community and insurance companies. This chart of overall risk appetite in the healthcare sector shows how willing investors are to invest in companies whose revenue depends on complex medical decision-making processes.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Exagen Inc.
Exagen is a company specializing in diagnostic tests for the detection and monitoring of autoimmune diseases. This chart reflects market expectations for the future of personalized diagnostics. The assessment depends on the volume of tests performed, insurance reimbursement, and the company's ability to bring new innovative diagnostic products to market.
%20P%2FE%20Exagen%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Exagen-Inc.&v=1772658662802 "Chart of the company's future (projected) P/E Exagen Inc.")
Future (projected) P/E of the market segment - Medanalysis
Exagen Inc. specializes in the development and sale of diagnostic tests for autoimmune diseases. This chart reflects investor expectations for the company's profitability relative to the medical diagnostics sector. It allows one to assess the market's perception of the potential of its unique tests to improve early diagnosis.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772658663015 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Exagen specializes in developing and selling diagnostic tests for autoimmune diseases. Despite the general market fluctuations shown by this chart, Exagen's business operates according to its own rules. Demand for its tests is driven by decisions by doctors and insurance companies, not by the overall state of the economy, making its business model relatively acyclical.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772658663049 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Exagen Inc.
Exagen Inc. specializes in diagnostic tests for autoimmune diseases, helping doctors make accurate diagnoses. The company's financial success depends on the widespread adoption of its tests and insurance coverage. This chart shows how successfully the company is commercializing its innovations in medical diagnostics.
Profit of companies in the market segment - Medanalysis
Exagen specializes in diagnostic tests for autoimmune diseases. This chart shows profitability in the medical diagnostics sector. For Exagen, this reflects demand for accurate and timely tests that help doctors make diagnoses. Growth in the sector underscores the importance of personalized medicine, where Exagen plays a key role.
Overall market profit
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. Demand for its products is driven by the need for accurate diagnostics among physicians and patients. This market is growing thanks to improved understanding of these diseases and is not affected by short-term economic fluctuations, as can be seen in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Exagen Inc.
Exagen specializes in diagnostic tests for autoimmune diseases, particularly lupus. The revenue forecast presented here depends on the testing volume of its flagship product, AVISE CTD. Analysts are assessing the company's efforts to increase market penetration and expand the use of its tests by rheumatologists.
%20profit%20of%20the%20company%20Exagen%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Exagen-Inc.&v=1772658663188 "Graph of future (projected) profit of the company Exagen Inc.")
Future (predicted) profit of companies in the market segment - Medanalysis
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. The revenue forecast for the medical analytics sector reflects the growing need for accurate and early diagnostics. This chart shows the analysts' collective view on the market's future, which hinges on the adoption of new tests in clinical practice and their insurance coverage.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772658663208 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Exagen specializes in diagnostic tests for autoimmune diseases. Demand for its services depends on the volume of tests performed and their reimbursement by insurers. The market profit forecasts shown here provide context for the overall health of the healthcare system and its ability to fund advanced diagnostics.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772658663223 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Exagen Inc.
Exagen specializes in diagnostic tests for autoimmune diseases. This chart shows how investors value its revenue, which is based on the number of tests performed. This valuation reflects the potential of its unique diagnostic products and its ability to convince physicians and insurers of their clinical and economic value.
P/S market segment - Medanalysis
Exagen specializes in the development and sale of diagnostic tests for autoimmune diseases. Accurate and early diagnosis is key to successful treatment. This chart reflects the average revenue estimate for the sector, helping to understand the premium the market pays for Exagen's innovative diagnostic solutions and their contribution to medicine.
P/S of the market as a whole
Exagen specializes in the development and sale of diagnostic tests for the detection and monitoring of autoimmune diseases such as lupus. The company's growth depends on the adoption of its tests in clinical practice. This chart provides an overview of the market's perception of revenue prospects in the innovative medical diagnostics sector, given overall economic trends.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Exagen Inc.
Exagen specializes in diagnostic tests for autoimmune diseases such as lupus. This chart shows how investors estimate the company's future revenue from test sales. It reflects the growing need for accurate and early diagnosis of complex rheumatological diseases.
%20P%2FS%20Exagen%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Exagen-Inc.&v=1772658663429 "The graph of the company's future (projected) P/S Exagen Inc.")
Future (projected) P/S of the market segment - Medanalysis
Exagen Inc. specializes in diagnostic tests for autoimmune diseases, helping physicians make accurate diagnoses. Its future sales are dependent on the acceptance of its tests by the medical community and the reimbursement system. This graph reflects market expectations regarding the commercial success of its unique diagnostic platform.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772658663451 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. Demand for their innovative assays depends on acceptance by the medical community and insurance companies. This chart, reflecting the overall investment climate, is important for Exagen. Market optimism supports funding for medical innovation and the healthcare system's readiness to implement new tests.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772658663480 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Exagen Inc.
Exagen specializes in autoimmune disease diagnostics, offering physicians its AVISE line of tests to help identify conditions like lupus. This chart reflects the volume of diagnostic tests performed. The company's revenue growth is directly related to how widely rheumatologists use its tests to accurately diagnose their patients.
Sales of companies in the market segment - Medanalysis
Exagen specializes in the development and commercialization of diagnostic tests that help doctors diagnose and treat autoimmune diseases like lupus. Their flagship test, AVISE, is a key tool for rheumatologists. This chart shows that virtually all of the company's revenue is generated by these complex tests.
Overall market sales
Exagen specializes in the development and sale of diagnostic tests for autoimmune diseases. Early and accurate diagnosis is crucial for effective treatment. This overall economic activity chart includes the healthcare sector, where Exagen contributes by providing physicians with innovative tools to combat complex diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Exagen Inc.
Exagen is a company specializing in diagnostic tests for autoimmune diseases, particularly lupus. Its tests help doctors make more accurate diagnoses. This chart shows analysts' expectations for growth in testing volumes and the adoption of Exagen's diagnostic products in rheumatology practice, which determines future revenue.
%20sales%20of%20the%20company%20Exagen%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Exagen-Inc.&v=1772658663584 "Schedule of future (projected) sales of the company Exagen Inc.")
Future (projected) sales of companies in the market segment - Medanalysis
Exagen specializes in the development and sale of diagnostic tests for autoimmune diseases such as lupus. This chart displays projected revenue for the entire medical diagnostics industry. It illustrates the expected growth of the testing market, driven by both an aging population and the development of personalized medicine, where Exagen excels.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772658663632 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Exagen Inc., which specializes in diagnostic tests for autoimmune diseases, sees this chart as an indicator of healthcare accessibility. Rising overall economic forecasts ensure stable healthcare funding. This allows doctors to more frequently prescribe advanced diagnostic tests for accurate diagnoses, which is the core of Exagen's business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772658663656 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Exagen Inc.
Exagen Inc. is a diagnostic company focused on developing and selling tests for autoimmune diseases. Its financial health depends on the acceptance of its tests by the medical community and insurance coverage. This chart illustrates the company's complex economics: the balance between high research and marketing costs and revenue from commercializing the tests.
Market segment marginality - Medanalysis
Exagen specializes in developing and selling diagnostic tests for autoimmune diseases. This indicator reflects the commercial value of its unique tests. Superiority over competitors will demonstrate high diagnostic accuracy and the trust of the medical community in its products.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Exagen Inc.
Exagen specializes in diagnostic tests for autoimmune diseases, helping doctors make accurate diagnoses. This chart shows the size of the team of scientists and lab technicians who develop and perform these complex tests. Their work provides critical information for the treatment of diseases such as lupus and rheumatoid arthritis.
Share of the company's employees Exagen Inc. within the market segment - Medanalysis
Exagen Inc. specializes in the development and sale of diagnostic tests for autoimmune diseases. Accurate laboratory diagnostics require a team of highly qualified laboratory technicians and scientists. This chart reflects the research intensity of the company's business, showing the proportion of specialists in the narrow field of autoimmune diagnostics it concentrates on improving patients' lives.
Number of employees in the market segment - Medanalysis
Exagen specializes in developing diagnostic tests for autoimmune diseases such as lupus. Early and accurate diagnosis in this area is critical. This chart reflects the growth of our team of scientists and laboratory technicians who are creating innovative tools that help doctors make accurate diagnoses and select effective treatments for patients.
Number of employees in the market as a whole
Exagen Inc. specializes in diagnostic tests for autoimmune diseases, helping doctors make accurate diagnoses. The overall employment trend shown in the chart reflects the economic health needed to fund cutting-edge medical research. A stable economy allows the healthcare system to implement innovative tests like those offered by Exagen.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Exagen Inc. (XGN)
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. For companies like this, this chart shows how the market values their scientific potential. Their high market capitalization per employee speaks to the value of their patents and diagnostic platforms. A small team of researchers is developing technology that could change diagnostic approaches for millions of people.
%20of%20the%20company%20Exagen%20Inc.%20(XGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Exagen-Inc.-XGN&v=1772658664243 "Chart of market capitalization per employee (in thousands of dollars) of the company Exagen Inc. (XGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Exagen Inc. is a life sciences company focused on autoimmune disease diagnostics. Its value lies in its unique testing and research data, not its large staff. This metric compares Exagen's market valuation per employee to the industry average, reflecting investor confidence in its diagnostic technologies.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772658664318 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Exagen specializes in diagnostic tests for autoimmune diseases such as lupus. In the medical diagnostics industry, this metric reflects the value of its unique tests and intellectual property. It shows how the market values the company's ability to help doctors make accurate diagnoses, which translates into high cost per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772658664433 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Exagen Inc. (XGN)
Exagen is a diagnostic company specializing in tests for autoimmune diseases. This chart shows how effectively their lab and R&D team can monetize their unique tests. Profitability in this business depends on securing insurance coverage and the ability to process thousands of samples with high margins.
%20Chart%20Exagen%20Inc.%20(XGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Exagen-Inc.-XGN&v=1772658664463 "Company Profit Per Employee (in thousands of dollars) Chart Exagen Inc. (XGN)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Exagen is a diagnostic company specializing in tests for autoimmune diseases, particularly lupus. In the medical analysis industry, staff efficiency is a balance between highly qualified lab technicians, R&D, and sales. This chart shows industry benchmark profit per employee, demonstrating how successfully Exagen is scaling its unique tests.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772658664571 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Exagen is a diagnostic company specializing in complex tests for autoimmune diseases, primarily lupus (the AVISE test). It's a CLIA-compliant, in-house laboratory business. This chart shows how effectively their sales team convinces doctors (rheumatologists) to order their tests and their lab staff to process them profitably.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772658664576 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Exagen Inc. (XGN)
Exagen Inc. specializes in diagnostic tests for autoimmune diseases. This chart shows how research and development converts into revenue. The growth reflects the increasing volume of tests performed and their acceptance by the medical community. High labor productivity is the result of automated laboratory processes.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Exagen-Inc.-XGN&v=1772658664581 "Sales chart per company employee Exagen Inc. (XGN)")
Sales per employee in the market segment - Medanalysis
Exagen is a diagnostics company. Their business is a lab where they conduct their proprietary tests (for example, for autoimmune diseases). Efficiency here is a balance between highly qualified lab technicians, R&D, and automation. This chart shows how productive their model (test sales) is in generating revenue per employee.
Sales per employee for the market as a whole
Exagen is a diagnostic company specializing in sophisticated blood tests for the early detection of autoimmune diseases (such as lupus). Their business is a high-tech laboratory. This chart shows how effectively their team of scientists and lab technicians converts tests into actual revenue for the company.
Short shares by company, segment and market as a whole
Shares shorted by company Exagen Inc. (XGN)
Exagen (XGN) is a diagnostics company specializing in the development and sale of tests (including its flagship AVISE) for diagnosing and monitoring autoimmune rheumatic diseases. This chart measures bearish bets. A rise in shorts may signal investor doubts that insurance companies will broadly cover their tests or skepticism about their commercial success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Exagen-Inc.-XGN&v=1772658664698 "Short Shares Chart for the Company Exagen Inc. (XGN)")
Shares shorted by market segment - Medanalysis
Exagen (XGN) is a diagnostics company specializing in tests for detecting and monitoring autoimmune diseases, particularly lupus. This chart highlights the general skepticism in the medical diagnostics sector. It summarizes bearish bets, reflecting investor concerns about changes in the reimbursement system or competition.
Shares shorted by the overall market
Exagen provides diagnostic tests for autoimmune diseases. This is a specialized, in-demand medical service. While healthcare is generally a defensive sector, high market anxiety (shown in this chart) could still put pressure on small, fast-growing medical technology companies that have yet to achieve stable profitability.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Exagen Inc. (XGN)
Exagen (XGN) is a molecular diagnostics company. They offer tests (such as AVISE) for diagnosing and monitoring autoimmune rheumatic diseases like lupus. This chart measures momentum. It shows "overbought" (above 70) amid rising testing volumes or "oversold" (below 30) amid concerns about Medicare rate changes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Exagen-Inc.-XGN&v=1772658664775 "RSI 14 indicator chart for the company's stock Exagen Inc. (XGN)")
RSI 14 Market Segment - Medanalysis
Exagen (XGN) is a diagnostics company specializing in autoimmune diseases. Their flagship test helps doctors diagnose and manage patients with lupus. This chart measures the pulse of the Medical Analysis sector. It helps investors understand whether XGN's performance reflects their unique testing or whether the entire industry is overheated or oversold.
RSI 14 for the overall market
Exagen (XGN) provides diagnostic tests. This chart shows that its business is "defensive." Demand for diagnostics (for rheumatology) is unaffected by euphoria or panic. During periods of market panic, investors seek safe havens in companies with completely non-cyclical demand.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XGN (Exagen Inc.)
Exagen is a life sciences company that has developed a portfolio of diagnostic tests (including AVISE) for the detection and monitoring of autoimmune rheumatic diseases such as lupus. This chart shows the average price target from analysts assessing testing volumes and insurance coverage.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XGN-Exagen-Inc.&v=1772658664959 "A chart showing analyst consensus forecasts for the expected stock price. XGN (Exagen Inc.)")
The difference between the consensus estimate and the actual stock price XGN (Exagen Inc.)
Exagen (XGN) is a diagnostics company focused on autoimmune diseases. Its flagship test (AVISETM) helps doctors diagnose lupus. This chart shows the difference between the consensus estimate and the price. It reflects whether analysts believe this niche test will be widely adopted by doctors.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XGN-Exagen-Inc.&v=1772658665004 "A chart showing the difference between the consensus forecast and the actual stock price. XGN (Exagen Inc.)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Exagen (XGN) is a diagnostics company focused on "invisible" diseases. Its tests help doctors diagnose complex autoimmune diseases such as lupus. This chart shows analysts' overall expectations for the medical testing sector. It reflects whether experts believe the complex diagnostics market will grow or whether they see pricing pressure.
Analysts' consensus forecast for the overall market share price
Exagen is a "diagnostic" "company" "focused" on "tests" "for" "autoimmune" "diseases" (lupus). This chart of overall market sentiment is important. "Optimism" = "the market" "is" "willing" to "fund" R&D of "new" "tests." In a "recession" (pessimism), "investors" "value" "protected" "demand" for "existing" "tests."
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Exagen Inc.
Exagen (XGN) is a diagnostics company. Their signature product is their proprietary blood tests (AVISETM) for diagnosing and monitoring autoimmune diseases (lupus, rheumatoid arthritis). This chart is an adoption indicator. It measures their ability to convince rheumatologists to use their (more expensive) proprietary tests instead of standard ones.
AKIMA Market Segment Index - Medanalysis
Exagen is a company specializing in diagnosing autoimmune diseases, particularly lupus, using its proprietary tests (AVISe). This chart shows the average index for the medical analysis sector. It allows investors to assess how Exagen, with its focus on complex diagnostics, outperforms or underperforms the average.
The AKIM Index for the overall market
Exagen is a diagnostic company specializing in autoimmune diseases (lupus, rheumatoid arthritis). AVISE tests. This chart, reflecting the market average, is a backdrop. It helps assess how this diagnostic growth story, dependent on insurer reimbursements, compares to overall macroeconomic trends.
